Latest Breaking News On - Shailesh siroya - Page 1 : comparemela.com

Bal Pharma hit an upper circuit of 5% at Rs 98.50 after the company announced the launch of favipiravir formulation into Indian market, under the brand name BALflu. Favipiravir is an emerging anti-viral drug used for patients with mild to moderate COVID-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus. BALflu (favipiravir) is a broad-spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, filovirus, west nile virus, food & mouth disease virus and lassa virus.

Shailesh siroyaBal pharmaDrug controller generalCapital marketPhysical sciencesAntiviral drugsChemical compoundsCovid 19K 05Harmaceuticals necBal pharmaDirector of the companyWest nileInfluenza virusபால் பார்மாமருந்து கட்டுப்படுத்தி ஜநரல்